Multiple sclerosis
Drug research and approvals for multiple sclerosis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 18, 2026, 432 studies of multiple sclerosis are recruiting on ClinicalTrials.gov, Health Canada has authorized 94 drug trials for it since 2013, FDA has 8 approved and 15 open orphan designations naming it, and the EU has 29 authorised medicines for it.
- Recruiting worldwide: 432
- Trials authorized in Canada: 94
- FDA orphan approvals: 8
- EU medicines: 29
Recruiting now
Newest start dates first, of 432 recruiting on ClinicalTrials.gov ↗- Evaluation of an Online, On Demand Multimodal Wellness Program to Reduce Fatigue and Improve Quality of Life in…NCT07831928 · Not applicable · University of Iowa · starts Dec 15, 2026
- Eccentric vs. Concentric Ankle Training in Multiple SclerosisNCT07937345 · Not applicable · Al Hayah University In Cairo · starts Nov 18, 2026
- Switch to Ofatumumab and Level of ImmunoglobulinsNCT07625800 · Not reported · University Hospital, Lille · starts Oct 12, 2026
- The Effects of Synchronous and Asynchronous Pilates Training Based on Telerehabilitation on Core Stabilization,…NCT07893925 · Not applicable · Yuzuncu Yil University · starts Oct 12, 2026
- REAL-MS: Observational Database Study of AHSCT and MS TherapiesNCT07899502 · Not reported · Imperial College London · starts Oct 7, 2026
- A Phase 2a Study of SUN-627 in Participants With Non-Active Secondary Progressive and Primary Progressive Multiple…NCT07840326 · Phase 2 · Sundance Biosciences, Inc. · starts Oct 1, 2026
- A Phase 1/2a Study of Oral PRO-1562 in Healthy Subjects and Patients With Relapsing Multiple SclerosisNCT07826689 · Phase 1 / Phase 2 · Progentos Therapeutics · starts Oct 1, 2026
- A Study to Describe Multiple Sclerosis Patients Treated With Tolebrutinib as Per Label in a Real-world SettingNCT07898371 · Not reported · Sanofi · starts Oct 1, 2026
- Early Versus Delayed Start of Ocrevus Zunovo for Relapsing Multiple SclerosisNCT07878923 · Not reported · Oklahoma Medical Research Foundation · starts Sep 30, 2026
- A Study of IMS001 in Patients With Multiple SclerosisNCT07935031 · Phase 1 · Zhuhai Hengqin ImStem Biotechnology Co., Ltd. · starts Sep 28, 2026
Drug pipeline
31 approved, 52 in phase 3, 66 in phase 2, 46 in phase 1 or earlier; from ChEMBL's drug indications, furthest stage reached for this conditionApproved: Interferon BETA-1A, Teriflunomide, Ocrelizumab, Dalfampridine, Glatiramer acetate, Fingolimod, Ofatumumab, Natalizumab, Dimethyl fumarate, Interferon BETA-1B, Cladribine, Alemtuzumab, Corticotropin, Peginterferon BETA-1A, Ozanimod, Daclizumab, Ponesimod, Prednisone, Diroximel fumarate, Baclofen, Mitoxantrone, Siponimod, Dantrolene, Methylprednisolone hemisuccinate, Dexamethasone, Monomethyl fumarate, Lincomycin, Mycophenolic acid, Triamcinolone acetonide, Prednisolone acetate, Prednisolone phosphoric acid
- Rituximab
- Phase 3 B-lymphocyte antigen CD20 binding agent
- Tolebrutinib
- Phase 3 Tyrosine-protein kinase BTK inhibitor
- Cyclophosphamide anhydrous
- Phase 3 DNA inhibitor
- Laquinimod
- Phase 3
- Nabiximols
- Phase 3
- Ublituximab
- Phase 3 B-lymphocyte antigen CD20 binding agent
- Interferon beta
- Phase 3
- Acyclovir
- Phase 3 Human herpesvirus 1 DNA polymerase inhibitor
- Influenza virus vaccine
- Phase 3 Biological vaccine - induces immune response
- Acetaminophen
- Phase 3 Cyclooxygenase inhibitor
- Methylphenidate
- Phase 3 Dopamine transporter inhibitor
- Memantine
- Phase 3 Glutamate [NMDA] receptor negative allosteric modulator
- Minocycline
- Phase 3 Bacterial 70S ribosome inhibitor
- Cholestyramine
- Phase 3 Bile acids sequestering agent
- Fenebrutinib
- Phase 3 Tyrosine-protein kinase BTK inhibitor
- Vidofludimus
- Phase 3 Dihydroorotate dehydrogenase inhibitor
- Biotin
- Phase 3
- Frexalimab
- Phase 3
- Methotrexate
- Phase 3 Dihydrofolate reductase inhibitor
- Onabotulinumtoxina
- Phase 3 Synaptosomal nerve-associated protein 25 (SNAP-25) inhibitor
- Peginterferon ALFA-2B
- Phase 3 Interferon alpha/beta receptor agonist
- Terfenadine
- Phase 3 Histamine H1 receptor antagonist
- Cetirizine
- Phase 3 Histamine H1 receptor antagonist
- Dexchlorpheniramine
- Phase 3 Histamine H1 receptor antagonist
- Diphenhydramine
- Phase 3 Histamine H1 receptor antagonist
- Ergocalciferol
- Phase 3 Vitamin D receptor agonist
- Amantadine
- Phase 3 Glutamate [NMDA] receptor antagonist
- Masitinib
- Phase 3 Fibroblast growth factor receptor 3 inhibitor
- Arbaclofen placarbil
- Phase 3 GABA-B receptor agonist
- Evobrutinib
- Phase 3 Tyrosine-protein kinase BTK inhibitor
Showing the 30 furthest along of 164 in trials.
How its trials ended
3,166 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 666 whose ending is known, 45% met their primary endpoint, 8% missed it and 47% stopped early.
- Completed, result not reported1,42545%
- Ongoing67821%
- Status unknown39713%
- Met its primary endpoint3009%
- Stopped: other or unclear1615%
- Stopped: enrollment or feasibility672%
- Missed its primary endpoint522%
- Stopped: sponsor or business decision461%
- Stopped: lack of efficacy241%
- Stopped: funding150%
- Stopped: safety10%
Trials authorized in Canada
The 10 newest of 94; search them all in Canada trials| Sep 17, 2026 | A phase 3 extension study to investigate long-term safety and tolerability of frexalimab in participants with multiple sclerosisFrexalimab (SAR441344) | Sanofi-Aventis Canada Inc | Pending |
| Apr 29, 2026 | A phase 3, randomized, double-blind, efficacy and safety study comparing orelabrutinib to placebo in patients with non-active secondary progressive multiple…Orelabrutinib (ICP-022, ZB020) | Zenas Biopharma (USA) LLC | Pending |
| Apr 28, 2026 | A phase 3, randomized, double-blind, efficacy and safety study comparing orelabrutinib to placebo in patients with primary progressive multiple sclerosisOrelabrutinib (ICP-022, ZB020) | Zenas Biopharma (USA) LLC | Pending |
| Apr 9, 2026 | A phase III, open-label, single-arm, multi-center study to evaluate the safety and use of an on-body delivery system for the subcutaneous home administration…Ocrelizumab (RO4964913) | Roche | Closed |
| Dec 22, 2025 | A phase 1b, open-label, multi-center, randomized study evaluating the safety and tolerability of AZD0120, an autologous CD19/bcma targeting chimeric antigen…AZD0120 (GC012F) / Cyclophosphamide / Fludarabine phosphate | AstraZeneca Pharmaceuticals | Pending |
| Aug 25, 2025 | A randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy and safety of remibrutinib in patients with secondary progressive…Remibrutinib (LOU064) | Novartis Pharmaceuticals | Ongoing |
| Jun 6, 2025 | A phase 2, randomized, double-blind, four-arm, placebo-controlled, multicenter study assessing the efficacy, safety and tolerability of three doses of orally…BMS-986368 | Bristol-Myers Squibb | Ongoing |
| May 30, 2025 | The differential effects of thc vs. cbd on cognition in persons with msMPL-013 (tetrahydrocannabinol-cbd) / MPL-014 (cannabidiol-thc) | University of Calgary | Ongoing |
| Apr 24, 2025 | A randomized, open-label, parallel-group, non-inferiority study comparing efficacy, safety, and tolerability of remibrutinib after switching from ocrelizumab…Remibrutinib (LOU064) | Novartis Pharmaceuticals | Ongoing |
| Dec 23, 2024 | Intermittent low oxygen breathing: a first study testing different disease stages in people living with multiple sclerosis (LOXYMS)Oxygen | University of Saskatchewan | Ongoing |
FDA orphan designations
Approved first, then open designations, newest first; 15 of 23| Sep 18, 2019 | OzobaxTreatment of spasticity resulting from multiple sclerosis, particularly for the relief of flexor spasms and concomitant pain, clonus, and… | Metacel Pharmaceuticals, LLC | Approved |
| Jan 22, 2010 | AmpyraTreatment to improve walking in patients with multiple sclerosis | Acorda Therapeutics | Approved |
| Oct 13, 2000 | NovantroneReducing neurologic disability and/or the frequency of clinical relapses in patients with secondary (chronic) progressive, progressive… | Serono, Inc. | Approved |
| Oct 13, 2000 | NovantroneReducing neurologic disability and/or the frequency of clinical relapses in patients with secondary (chronic) progressive, progressive… | Serono, Inc. | Approved |
| Dec 20, 1996 | CopaxoneFor reduction of the frequency of relapses in patients with relapsing-remitting multiple sclerosis. | Teva Pharmaceuticals USA | Approved |
| May 17, 1996 | AvonexTreatment of relapsing forms of multiple sclerosis to slow the accumulation of physical disability and decrease the frequency of clinical… | Biogen, Inc. | Approved |
| Jul 23, 1993 | BetaseronIn ambulatory patients with relapsing-remitting multiple sclerosis to reduce the frequency of clinical exacerbations. | Chiron Corp. & Berlex Laboratories | Approved |
| Jun 25, 1992 | Lioresal IntrathecalManagement of severe spasticity of spinal cord origin in patients who are unresponsive to oral baclofen therapy or experience intolerable… | Medtronic, Inc. | Approved |
| Apr 6, 2020 | Fixed combination of diroximel fumarate and aspirinTreatment of patients with multiple sclerosis who experience the fumarate flush | Vitalis, LLC | Designated |
| Apr 6, 2020 | Fixed combination of monomethyl fumarate and aspirinTreatment of patients with multiple sclerosis who experience the fumarate flush | Vitalis, LLC | Designated |
| Sep 27, 2018 | Fixed combination of dimethyl fumarate and aspirin (162mg)Treatment of multiple sclerosis in patients who experience dimethyl fumarate flushing | Vitalis, LLC | Designated |
| Sep 1, 2015 | Modified a-cobratoxinTreatment of pediatric multiple sclerosis (0 through 16 years of age). | Nutra Pharma Corporation | Designated |
| Feb 6, 2014 | T cell receptor (TCR) peptide (BV5S2, BV6S5, BV13S1) vaccineTreatment of Pediatric Multiple Sclerosis | Immune Response BioPharma, Inc. | Designated |
| Jan 12, 2011 | Anti-TCR murine monoclonal antibody (MAB, type IgM)Treatment of pediatric multiple sclerosis in patients less than or equal to 16 years of age | Tolera Therapeutics, Inc. | Designated |
| Apr 30, 2010 | Glyeraldehyde-3-phosphate dehydrogenaseTreatment of pediatric multiple sclerosis | BPT Pharmaceuticals, Inc. | Designated |
Medicines authorised in the EU
Newest first; 15 of 29Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA